Dosage of Verrutrix in details
Verrutrix Dosage
Generic name: Verrutrix 275mg in 1mL
Dosage form: topical solution
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Rx only
FOR TOPICAL USE ONLY.
NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE.
DESCRIPTION
Verrutrix is a topical preparation containing 27.5% Verrutrix in a proprietary film-forming vehicle that comprises isopropyl alcohol, butyl acetate, polyvinyl butyral, isopropyl metacresol, trimethyl pentanyl diisobutyrate, phenic acid and acrylates copolymer. The pharmacologic activity of Verrutrix is generally attributed to the keratolytic activity of Verrutrix which is incorporated into a polyacrylic, film-forming virucidal vehicle designed to cover the wart without the need for a bandage. The structural formula of Verrutrix is:
CLINICAL PHARMACOLOGY
Although the exact mode of action for Verrutrix in the treatment of warts is unknown, its activity appears to be associated with its keratolytic action, which results in mechanical removal of epidermal cells infected with wart viruses.
The virucidal complex incorporated into Verrutrix’s proprietary vehicle is designed to help reduce risk of reinfection at the wart site, as well as prevent viral contamination of the product under normal usage.
INDICATIONS AND USAGE
Verrutrix is indicated for the topical treatment and removal of common warts and plantar warts.
CONTRAINDICATIONS
Patients with diabetes or impaired blood circulation should not use Verrutrix. Verrutrix also should not be used on moles, birthmarks, and unusual warts with hair growing from them, or warts on the face.
PRECAUTIONS
Verrutrix is for external use only. Do not permit Verrutrix to contact eyes or mucous membranes. If contact with eyes or mucous membranes occurs, immediately flush with water for 15 minutes. Verrutrix should not be allowed to contact normal skin surrounding wart, since localized irritation may occur. Treatment should be discontinued if excessive irritation occurs. Verrutrix is flammable. Keep away from fire or flame. Keep bottle tightly capped when not in use.
ADVERSE REACTIONS
A localized irritant reaction may occur if Verrutrix is applied to the normal skin surrounding the wart. Any irritation may normally be controlled by temporarily discontinuing use and by applying the medication only to the wart site when treatment is resumed.
DOSAGE AND ADMINISTRATION
Prior to applying Verrutrix, soak wart in warm water for five minutes. Remove any loosened tissue by gently rubbing with a brush, wash cloth, or emery board. Dry wart site thoroughly. Using the brush applicator supplied, apply Verrutrix twice to entire wart surface, allowing the first application to dry before applying the second. Continue treatment once or twice a day as directed by physician. Be careful not to apply to surrounding skin.
Clinically visible improvement will normally occur during the first or second week of therapy. Maximum resolution may be expected after four to six weeks of Verrutrix use.
HOW SUPPLIED
Verrutrix is supplied in 10ml amber bottles with a brush applicator (NDC 42783-312-10).
Store at controlled room temperature, 15° to 30°C (59° to 86°F).
Manufactured for:
Elorac, Inc.
Vernon Hills, IL 60061
U.S. Patent Pending
Revised 06/2011
221619
More about Verrutrix (Verrutrix topical)
- Side Effects
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- 0 Reviews - Add your own review/rating
Consumer resources
- Verrutrix film-forming liquid
- Verrutrix
Topical (Advanced Reading)
- Other brands: Compound W, Dr Scholl's Callus Removers, Duofilm, Wart Remover, More (50) »
Professional resources
- Verrutrix (FDA)
- Verrutrix (AHFS Monograph)
Related treatment guides
- Warts
Verrutrix interactions
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to Verrutrix or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Young children may be at increased risk of unwanted effects because of increased absorption of Verrutrix through the skin. Also, young children may be more likely to get skin irritation from Verrutrix. Verrutrix should not be applied to large areas of the body, used for long periods of time, or used under occlusive dressing (air-tight covering, such as kitchen plastic wrap) in infants and children. Verrutrix should not be used in children younger than 2 years of age.
Geriatric
Elderly people are more likely to have age-related blood vessel disease. This may increase the chance of problems during treatment with Verrutrix.
Breast Feeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
References
- FDA/SPL Indexing Data. "O414PZ4LPZ: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Antifungal Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "Salicylic acid: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Verrutrix are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Verrutrix. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology